Incyte reports new data from hidradenitis suppurativa therapy trial

Incyte has reported new 52-week data from a Phase II trial of oral JAK1 inhibitor, povorcitinib (formerly INCB54707), in adult hidradenitis suppurativa (HS) patients.

The double-blind, dose-ranging, randomised, placebo-controlled Phase II trial was designed for assessing the safety and efficacy of povorcitinib in these patients.